Page 10 - CUA2018 Abstracts - Oncology-Bladder

Poster session 10: Other Oncology II

de l’Université de Montréal, Montreal, QC, Canada; Department of Results: We demonstrated an association between a high nuclear fre-
13
Medicine and Urology, Dalhousie University, Halifax, NS, Canada quency of NF–kB p65 (cutoff 3%) and increase risk of biochemical
Study Groups: Canadian Kidney Cancer information system (CKCis), relapse, bone metastasis, and prostate cancer–specific mortality in valida-
Kidney Cancer Research Network of Canada (KCRNC). tion series. In multivariate analyses on the validation cohort, p65 remained
Introduction: In Canada, second–line (2L) treatment of metastatic renal independent from clinical parameters.
cell carcinoma (mRCC) (post–first–line [1L] vascular endothelial growth Conclusions: Our study recapitulates the previous observation linking
factor–targeted therapy [VEGF–TT]) includes everolimus (EVE), axitinib NF–kB p65 with disease progression using a large cohort of Canadian men
(AX), and nivolumab. Prior to July 2017, the pan–Canadian Oncology and underscores the suitability of CPCBN TMAs for biomarker validation.
Drug Review (pCODR) indicated that AX could only be used if intolerance It also highlights its role as a predictor of bone metastasis and prostate
or a contraindication to EVE. This study aimed to determine whether or not cancer–specific survival.
AX is at least an equivalent alternative for 2L treatment so that AX could References:
be equally accessible for mRCC patients (pts) across Canada. 1. The Terry Fox Institute. Canadian Prostate Cancer Biomarker
Methods: Pt data were collected from the Canadian Kidney Cancer infor- Network. Available at http://www.tfri.ca/en/research/translational–
mation system (CKCis), a prospective database of pts with RCC. Pts who research/cpcbn.aspx. Accessed March 30, 2 018.
had 1L VEGF–TT (sunitinib or pazopanib), and were subsequently treated 2. Gannon PO, Lessard L, Stevens LM, et al. Large–scale indepen-
with either 2L AX or EVE were analyzed. Time to treatment failure (TTF, dent validation of the nuclear factor–kappa B p65 prognostic bio-
time from starting 2L therapy to stopping 2L therapy or loss to followup) marker in prostate cancer. Eur J Cancer 2013;49:2441–8. https://doi.
and overall survival (OS, time from starting 2L therapy to death or loss org/10.1016/j.ejca.2013.02.026
to followup) were calculated (Kaplan Meier method). 3. Labouba I, Le Page C, Communal L, et al. Potential cross–talk
Results: A total of 1168 pts were treated with 1L VEGF–TT. The study between alternative and classical NF–κB pathways in prostate can-
cohort who received either 2L AX or EVE was 337 patients; 108 AX and cer tissues as measured by a multi–staining immunofluorescence
229 EVE. Baseline characteristics will be presented. The median TTF was co–localization assay. PLoS One 2015;10:e0131024. https://doi.
greater for AX than EVE (5.45 m vs 3.78 m; p=0.034). There was no org/10.1371/journal.pone.0131024
significant difference in median OS between AX and EVE (10.91 m vs.
14.29 m; p=0.158). More pts received further therapy in the EVE group UP–10.3
than the AX group (45% vs 33%; p=0.031).
Conclusions: AX had a statistically better TTF than EVE in the 2L setting Outcome of 1006 prostate cancer patients with prostate–specific
post–1L VEGF–TT. Given this data, 2L AX should be considered an option antigen of 50 ug/L or more 2 2 1
1
1
for all pts in Canada post–1L VEGF–TT. Although the EVE group had a Patricia Tai , Asim Amjad , Arbind Dubey , Rashmi Koul , Nelson Leong ,
1
3
better OS, this was not statistically significant and may be due to the EVE Evgeny Sadikov , David Skarsgard
1
group receiving more subsequent lines of therapy. A request for advice Department of Radiation Oncology, Allan Blair Cancer Centre, Regina,
2
was submitted to pCODR from the Provincial Advisory Group with this SK, Canada; Department of Radiation Oncology, CancerCare Manitoba,
3
data and resulted in a revised recommendation for equal access to both Winnipeg, MB, Canada; Department of Radiation Oncology, Tom Baker
2L AX and EVE as of July 2017. Cancer Centre, Calgary, AB, Canada
Introduction: There is limited information in the literature on outcome of
prostate cancer patients with prostate–specific antigen (PSA) of 50 ug/L or
UP–10.2 more. These patients were traditionally treated with androgen–deprivation
Evaluation of nuclear factor–kappa B p65 on the Canadian therapy (ADT) alone. Herein, we report the largest series in the world.
Prostate Cancer Biomarker Network tissue–microarray series Methods: Staging investigations include nuclear medicine bone scan and
reveals its usefulness for biomarkers validation computerized tomography scan. Since 2004, our multidisciplinary team
Véronique Ouellet , Andrée–Anne Grosset , Christine Caron , Gabriela adopted the American National Comprehensive Cancer Network and
1
1
1
Fragoso , Véronique Barrès , Nathalie Delvoye , Mathieu Latour , Canadian guidelines, modern radiotherapy (RT) techniques such as volu-
1,2
1
1
1
Dominique Trudel , Armen Aprikian , Alain Bergeron , Simone Chevalier , metric modulated arc therapy, dose–escalation, and increasing use of RT.
3
1,2
3,4
5
Ladan Fazli , Neil Fleshner , Martin Gleave , Pierre Karakiewicz , Louis Results: From 1990–2016, a total of 1006 patients were found (464 with
6
6
1,2
7
Lacombe , Jean–Baptiste Lattouf , Theodorus van der Kwast , Anne–Marie and 542 without clinical metastases). The median followup was 41.6
5
1,2
7
Mes–Masson , Fred Saad 1,2 months (range 1 day–200.4 months). Among the 464 metastatic patients,
1
1 Centre de recherche du Centre hospitalier de l’Université de Montréal, the median overall survival (OS) was 27.6 months (range1 day–157.9
Montreal, QC, Canada; Centre Hospitalier de l’Université de Montréal, months), with 86/464 (18.5%) alive at five years and 10/464 (2.1%) alive
2
Montreal, QC, Canada; McGill University Health Centre Research at 10 years. Palliative treatments include: ADT alone (426 cases), none (28
3
Institute, Montreal, QC, Canada; McGill University Health Centre, cases), RT (3 cases), RT+ADT+chemo (three cases), RT+ADT (two cases),
4
Montreal, QC, Canada; Centre Hospitalier Universitaire de Québec and ADT+chemotherapy (two cases). In comparison, the median OS of
5
– Université Laval, Quebec City, QC, Canada; Vancouver Prostate the 542 non–metastatic patients was 55.9 months (range 23 days–200.4
6
Centre, Vancouver, BC, Canada; University Health Network, Toronto, months). Their treatments include: ADT alone (305 cases), radical RT (136
7
ON, Canada cases), watchful waiting (81 cases), radical RT+ADT (12 cases), radical
Introduction: The Canadian Prostate Cancer Biomarker Network (CPCBN) prostatectomy (seven cases, all with PSA of 50–60 ug/L), and radical
assembled a multi–institutional tissue–microarray (TMA) resource com- RT+taxotere (one case).
posed of 1512 patients treated by radical prostatectomy. Biomarkers are Conclusions: We challenge the previous commonly held belief that non–
evaluated on a test series and promising results allowed access to the vali- metastatic patients with very high PSA level should be treated with ADT
dation TMA series. This richly annotated resource is available to research- only. Even for clinical metastatic disease, 18.5% patients were still alive
ers who wish to access a large cohort to validate prognostic biomark- at five years.
ers. Over the last decade, nuclear factor–kappa B (NF–kB) p65 showed
1
a reproducible association of its nuclear localization and a patient’s risk
of biochemical recurrence across several independent cohorts. Here,
2,3
we evaluated the CPCBN TMA–series for p65 expression.
Methods: Automated immunohistochemistry staining of p65 was per-
formed on the test and validation series and two independent observers
scored the frequency of p65 nuclear localization. TMA series contain
a minimum of three cores of tumour tissues. Statistical analyses were
performed using SPSS software.
CUAJ • June 2018 • Volume 12(6Suppl2) S121